Recap: Syneos Health Q1 Earnings

 

Shares of Syneos Health SYNH remained unaffected after the company reported Q1 results.

Quarterly Results

Earnings per share increased 16.18% over the past year to $0.79, which beat the estimate of $0.75.

Revenue of $1,209,000,000 up by 3.96% year over year, which beat the estimate of $1,190,000,000.

Guidance

Syneos Health raised FY21 adjusted EPS guidance from $4.09-$4.38 to $4.17-$4.42.

The company reaffirmed sales guidance of $5.125B-$5.325B .

Details Of The Call

Date: Apr 29, 2021

Time: 08:00 AM

ET Webcast URL: https://www.directeventreg.com/der/toRegistration.action

Price Action

Company's 52-week high was at $89.95

52-week low: $50.27

Price action over last quarter: Up 15.38%

Company Description

Syneos is a global contract research and outsourced commercialization organization that provides services to pharmaceutical and biotechnology firms. Its clinical solutions segment offers early- to late-stage clinical trial support that ranges from specialized staffing models to strategic partnerships that oversee nearly all aspects of a drug program, while the company's commercialization solutions includes outsourced sales, consulting, public relations, and advertising services.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!